Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocuronium neuromuscular blockade in elderly patients with sarcopenia
ChiCTR2600132570Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Yangzhou University
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rocuronium in Sarcopenia (2 arms), sponsored by The Affiliated Hospital of Yangzhou University. Primary endpoints: Onset time of rocuronium (S0), Duration of complete neuromuscular blockade (S1) and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
rocuronium
03
Conditions
Sarcopenia
Beyond the preview
Go deeper on ChiCTR2600132570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132570.